glp-1 gip What is and GIP? Dual-action weight loss (UK) GIP Receptor Agonism Attenuates GLP-1

Individual response varies significantly regardless of medication selection

investigated the synergistic effects of MSTN inhibitors and GLP-1 agonists by administering apitegromab in combination with semaglutide, a GLP-1 agonist, and tirzepatide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide, in patients with obesity (NCT06445075)

It is also important to note that decreased fluid intake and fluid loss that might result from nausea and vomiting, the main adverse effects of these agents, can further injure the kidneys

45 Conversely, the relative increase in heart rates secondary to GLP-1 RAs may be potentially beneficial in HFpEF due to the high prevalence of chronotropic incompetence in these patients

doi:10.1097/fbp.0000000000000818 16.Garvey WT, Blher M, Osorto Contreras CK, et al

[4] For obesity, semaglutide 2.4mg (Wegovy) is recommended only through specialist weight management services (TA875)